Clinical Trial Update: A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China

View source ↗

Summary

A completed real-world study in China evaluated the safety and effectiveness of omalizumab (Xolair) for pediatric chronic spontaneous urticaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Status: COMPLETED